Lv3
318 积分 2025-04-27 加入
The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives
27天前
已完结
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
1个月前
已完结
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
1个月前
已完结
Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies
1个月前
已完结
Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies
1个月前
已完结
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
1个月前
已完结
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
1个月前
已关闭
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
2个月前
已关闭
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
2个月前
已完结
皖公网安备34019202002308
